Billionaire Andreas Halvorsen’s Top Moves from Latest 13F

Viking Global was bullish on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) during the December quarter, as the fund increased its stake in the company by 16.17 million shares to 25.04 million shares. The expanded stake was valued at $1.64 billion at the end of December. In July 2015, the Israel-based Teva announced the acquisition of Allergan’s generics drug business for $33.75 billion in cash and approximately 100 million Teva shares, which will create the world’s largest maker of generic medicines if the deal is approved. This move will strengthen the global pharmaceutical company’s negotiating power with governments and private health insurers. Reportedly, the deal is anticipated to be finalized by early April. Analysts at Argus believe that the aforementioned acquisition will drive up operating efficiencies and sales, as well as improve margins. Argus recently reiterated the ‘Buy’ rating on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), but slashed the price target to $75 from $82. Billionaire John Paulson’s Paulson & Co represents the second-largest shareholder of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) within our database with 20.41 million shares as of December 31.